You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
泰格醫藥(300347.SZ):上半年淨利升183.66%至9.99億元
格隆匯 08-28 21:24

格隆匯 8 月 28日丨泰格醫藥(300347.SZ)披露2020年半年度報告,實現營業收入14.52億元,同比增長8.58%;歸屬於上市公司股東的淨利潤9.99億元,同比增長183.66%;歸屬於上市公司股東的扣除非經常性損益後的淨利潤3.03億元,同比增長5.32%;基本每股收益1.3444元。

報告期內,公司實現營業收入同比增長8.58%。主要由於臨牀試驗技術服務和臨牀試驗相關服務及實驗室服務產生的收入增加所致。

(1)臨牀試驗技術服務

報告期內,臨牀試驗技術服務實現主營業務收入7.11億元,同比增長12.18%,主要由於公司新增合併範圍的子公司北京雅信誠和上海謀思的臨牀試驗技術服務收入所致。

(2)臨牀試驗相關服務及實驗室服務

報告期內,臨牀試驗相關服務及實驗室服務實現主營業務收入7.34億元,同比增長5.3%,主要由於公司實驗室服務和臨牀試驗現場管理及患者招募服務業務規模增長所致。

(3)分地區服務

報告期內,境外營業收入6.06億元,佔比41.75%,境內營業收入8.46億元,佔比58.25%;上年同期境外營業收入佔比45.7%,境內營業收入佔比54.3%,本報告期境內營業收入佔比增加,主要由於公司境內創新藥臨牀試驗業務同比增長較快。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account